Opendata, web and dolomites


Improving diagnostics of respiratory diseases and boosting the COMAC MEDICAL Ltd. competitiveness and growth by validation of fractional EBT biomarker through new method of measurement and device

Total Cost €


EC-Contrib. €






 FrEBT project word cloud

Explore the words cloud of the FrEBT project. It provides you a very rough idea of what is the project "FrEBT" about.

annually    20    causing    pulmonology    disruptive    painful    children    network    ltd    technological    ip    filling    global    total    deaths    description    cancer    inflammatory    medical    market    10    mortality    specialisation    asia    commercial    diagnosis    invasive    markets    respiratory    financial    young    118    biomarker    assessing    people    regions    diagnostic    outcome    bln    managerial    profitability    lung    14    clinical    doctors    prognostic    12    feasibility    oncology    validate    full    breath    diseases    innovative    region    organizational    pulmonary    alternative    economic    obstructive    precise    share    healthcare    bulgaria    prove    exhaled    competitiveness    stages    organization    sme    solution    morbidity    worldwide    million    380    fractional    groups    temperature    service    innovation    population    gps    15    monitoring    specialists    device    workforce    saving    mln    risk    vulnerable    patients    comac    niche    eu28       socio    lives    phase1    elderly    countries    faster    trials    launch   

Project "FrEBT" data sheet

The following table provides information about the project.


Organization address
address: 131 ODRIN STR AP 22
city: SOFIA
postcode: 1303
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Bulgaria [BG]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMAC MEDICAL LTD BG (SOFIA) coordinator 50˙000.00


 Project objective

The innovation project objectives are to: 1/prove through a feasibility study the potential to validate the Fractional Exhaled Breath Temperature, via new viable and disruptive technological device, as a diagnostic, prognostic and monitoring biomarker for inflammatory and obstructive pulmonary diseases; 2/enhance the competitiveness and profitability of the full- service clinical research organization COMAC MEDICAL Ltd., operating via own network of partners in 14 countries from 3 European regions with population of over 118 mln. The commercial potential of the innovative solution is that it is a best alternative of the existing methods on market, saving great number of diagnosis‘ stages without any potential risk for the patients, being more precise, user friendly, non-invasive, less painful, faster, cost effective, covering vulnerable groups of children, young and elderly people, saving lives, increasing workforce capabilities. It is a response to the EU wide and global challenges related to the respiratory diseases causing high level of morbidity and mortality–at about 1 million deaths annually in the European Region; 2/3 of them in EU28, with total cost there of € 380 bln. The expected SME growth is 20%, leading to specialisation in Pulmonology and Oncology and filling a market niche. The SME will launch into new markets in Europe and Asia, increasing its market share in clinical trials - 12-15% in Bulgaria;10% in Europe and 2-5% worldwide. The outcome of the Phase1 project is a feasibility study, assessing the socio-economic, commercial, technical aspects of the innovation, based on 6 steps of activities on: the Description of the innovative solution;Market/Technical Feasibility;Financial/Economic Feasibility; Organizational/Managerial Feasibility;Risk assessment;IP Management. The targeted users are the patients through the healthcare systems and the doctors, specialists in respiratory diseases and lung cancer as well as the GPs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FREBT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FREBT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More